SOLIRIS®- the prospect of more relapse-free days SOLIRIS® (eculizumab) is indicated for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.1 Please refer to the SOLIRIS® Summary of Product Characteristics.
advance I am a healthcare professional registered in the EU I am not a
healthcare professional
Prior to prescribing please refer to the SOLIRIS® Summary of Product Characteristics.

* Based on safety data from 31 completed clinical studies that included 1,503 patients exposed to eculizumab in complement-mediated disease populations; including PNH, aHUS, refractory gMG and NMOSD.1

For NMOSD patients, reduction in the risk of disabling attacks can be possible1-3
Healthcare professionals are asked to report any suspected adverse reactions. Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following email: https://contactazmedical.astrazeneca.com/
SOLIRIS® (eculizumab) EU Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/ documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: December 2023. Pittock SJ, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625. Plus Supplementary materials. Wingerchuk DM, et al. long-term safety and efficacy of eculizumab in anti-aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021;89(6):1088–1098.